GlassScriptPhysician profile
Melissa Vitale
NPI 1952867681
$150,576.56
in general payments reported to CMS, 2019-2025
20 companies · $22K in 2025
The $22K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24K · 2022: $29K · 2023: $46K · 2024: $30K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $76K · Travel and Lodging: $15K · Food and Beverage: $4,867 · Consulting Fee: $870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $76,380.00 |
| Travel and Lodging | $15,195.16 |
| Food and Beverage | $4,866.86 |
| Consulting Fee | $870.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $144,968.95 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Abbvie INC. | $1,145.23 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,059.59 | 2021-2025 | Caplyta |
| Lundbeck LLC | $606.26 | 2021-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $589.46 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $388.98 | 2021-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $310.43 | 2021-2025 | Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $309.68 | 2021-2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $308.66 | 2021-2023 | Fanapt, Hetlioz |
| Alkermes, INC. | $254.08 | 2021-2024 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $246.20 | 2022-2024 | Auvelity |
| Bausch Health US, LLC | $115.84 | 2021-2025 | Wellbutrin, Aplenzin |
| E.R. Squibb & Sons, L.L.C. | $69.41 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $62.80 | 2021 | |
| Neos Therapeutics, LP | $45.58 | 2021-2024 | Adzenys Xr-Odt |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $25.66 | 2025 | Azstarys |
| Bioxcel Therapeutics, INC. | $18.72 | 2023 | Igalmi |
| Indivior INC. | $18.00 | 2023 | Perseris |
| Idorsia Pharmaceuticals US INC | $17.67 | 2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $15.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Vitale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.